The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
This panel highlights how different organizations in the biopharma supply chain are addressing the inherent challenges of producing and delivering cell and gene therapies and biologics.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Register for INVEST Precision Medicine to check out the life science track of the Pitch Perfect startup contest and hear compelling panel discussions on software supporting biopharma R&D, and the supply chain challenges of scaling production and delivering personalized therapies.
The company said it plans to expand into new supply chains for advanced therapeutics in addition to cell and gene therapies, as well as expanding its footprint in Europe and the Asia-Pacific region.
The partnership will combine Vineti's cloud-based system for cell therapy logistics with Deloitte Consulting's ConvergeHEALTH Patient Connect.
The San Francisco startup has a cloud-based platform to prevent supply chain mistakes in personalized cell and gene therapy where patients' re-engineered cells need to be delivered back to the correct individual.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
For all the complexity of CAR-T autologous transplant technology, GE Ventures spin-out Vineti has a simple question to ask: What if the wrong cells are infused back into the patient?